Stephens Consulting’s Krystal Biotech KRYS Stock Holding History

Stephens Consulting’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5	Closed	-$902	–	1608
2025 Q1	$902	Buy	+5	New	+$841	﹤0.01%	687

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Stephens Consulting's KRYS Position: Q2 2025 in Review

Stephens Consulting sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 5 shares — an estimated $902 sold.

Stephens Consulting first reported a position in KRYS in Q1 2025 and held it in 1 quarter. The position peaked at $902 in Q1 2025. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

Stephens Consulting reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 5 Krystal Biotech shares in Q2 2025, an estimated $902.
Stephens Consulting first reported a position in Krystal Biotech in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Krystal Biotech position peaked at $902 in Q1 2025.
275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.